** Shares of obesity drugmakers gain premarket after Pfizer PFE.N says it has discontinued development of experimental weight-loss pill danuglipron
** Eli Lilly LLY.N shares up 1.69% to $744.82 in premarket trading, while U.S. listed shares of Danish drugmaker Novo Nordisk NOVOb.CO rise 3.74% to $67.15
** Shares of obesity drug developer Viking Therapeutics VKTX.O jump 19.1% to $26.47, while Altimmune ALT.O rises 2.95% to $4.54
** Pfizer shares down marginally at $21.75 before the bell
** Up to last close, LLY down ~5%, VKTX down ~45%, while ALT down 39% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。